Classical and novel approaches to the preclinical testing of anxiolytics: A critical evaluation

Neuroscience and Biobehavioral Reviews

Volumn 37, Issue 10, 2013, Pages 2318-2330

  Haller, J ^a   Aliczki, M ^a   Gyimesine Pelczer, K ^a  

^a INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

Author keywords

Anxiety; Preclinical; Testing; Validity

Indexed keywords

ANXIOLYTIC AGENT;

ANXIETY; ANXIETY DISORDER; DISEASE MODEL; EXPERIMENTAL ANXIETY TEST; HUMAN; NONHUMAN; OBSESSIVE COMPULSIVE DISORDER; PANIC; POSTTRAUMATIC STRESS DISORDER; PREDICTIVE VALIDITY; PREDICTIVE VALUE; PRIORITY JOURNAL; REVIEW; SOCIAL STRESS;

ANXIETY; PRECLINICAL; TESTING; VALIDITY;

ANIMALS; ANTI-ANXIETY AGENTS; ANXIETY DISORDERS; DISEASE MODELS, ANIMAL; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; HUMANS; PREDICTIVE VALUE OF TESTS;

EID: 84890180547     PISSN: 01497634     EISSN: 18737528     Source Type: Journal    
DOI: 10.1016/j.neubiorev.2012.09.001     Document Type: Review

References (283)

1. Anon. A new antidepressant: desipramine hydrochloride (Norpramin, Pertofrane). The Journal of the American Medical Association 1965, 194:82-83.
2. Adamec R.E., Burton P., Blundell J., Murphy D.L., Holmes A. Vulnerability to mild predator stress in serotonin transporter knockout mice. Behavioural Brain Research 2006, 170:126-140.
3. Adamec R.E., Shallow T. Lasting effects on rodent anxiety of a single exposure to a cat. Physiology and Behavior 1993, 54:101-109.
4. Adams J.B., Pyke R.E., Costa J., Cutler N.R., Schweizer E., Wilcox C.S., Wisselink P.G., Greiner M., Pierce M.W., Pande A.C. A double-blind, placebo-controlled study of a CCK-B receptor antagonist, CI-988, in patients with generalized anxiety disorder. Journal of Clinical Psychopharmacology 1995, 15:428-434.
5. American Psychiatric Association, 1994. Diagnostic and Statistical Manual of Mental Disorders, fourth ed. Washington, DC.
6. Andersen S.L., Greene-Colozzi E.A., Sonntag K.C. A novel, multiple symptom model of obsessive-compulsive-like behaviors in animals. Biological Psychiatry 2010, 68:741-747.
7. Aron C., Simon P., Larousse C., Boissier J.R. Evaluation of a rapid technique for detecting minor tranquilizers. Neuropharmacology 1971, 10:459-469.
8. Assalian P., Rosengarten M.D., Phillips R. A comparative trial of the antidepressant, anxiolytic, and cardiovascular effects of trimipramine and doxepin in depressed hospitalized patients. Journal of Clinical Psychiatry 1985, 46:90-94.
9. Bailey J.E., Nutt D.J. GABA-A receptors and the response to CO(2) inhalation - a translational trans-species model of anxiety?. Pharmacology Biochemistry and Behavior 2008, 90:51-57.
10. Ballard T.M., Sänger S., Higgins G.A. Inhibition of shock-induced foot tapping behaviour in the gerbil by a tachykinin NK1 receptor antagonist. European Journal of Pharmacology 2001, 412:255-264.
11. Bandelow B., Sher L., Bunevicius R., Hollander E., Kasper S., Zohar J., Möller H.J. Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care. International Journal of Psychiatry in Clinical Practice 2012, 16:77-84.
12. Barsy B., Leveleki C., Zelena D., Haller J. The context specificity of anxiety responses induced by chronic psychosocial stress in rats: a shift from anxiety to social phobia?. Stress 2010, 13:230-237.
13. Barzaghi F., Fournex R., Mantagezza P. Pharmacological and toxicological properties of clobazam (1-phenyl-5-methyl-7-chloro-1,3,4,5-tetrahydro-2,4-diketo-3H-1,5-benzodiazepine): a new psychotherapeutic agent. Arzneimittel-Forschung 1973, 23:683-686.
14. Bass S.L., Gerlai R. Zebrafish (Danio rerio) responds differentially to stimulus fish: the effects of sympatric and allopatric predators and harmless fish. Behavioural Brain Research 2008, 186:107-117.
15. Bassi S., Albizzati M.G., Ferrarese C., Frattola L., Cesana B., Piolti R., Farolfi A. Alpidem, a novel anxiolytic drug. A double-blind, placebo-controlled study in anxious outpatients. Clinical Neuropharmacology 1989, 12:67-74.
16. Baudrie V., De Vry J., Broqua P., Schmidt B., Chaouloff F., Glaser T. Subchronic treatment with anxiolytic doses of the 5-HT1A receptor agonist ipsapirone does not affect 5-HT2 receptor sensitivity in the rat. European Journal of Pharmacology 1993, 231:395-406.
17. Bauer M., Pretorius H.W., Constant E.L., Earley W.R., Szamosi J., Brecher M. Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study. Journal of Clinical Psychiatry 2009, 70:540-549.
18. Belzung C., Berton F. Further pharmacological validation of the Balb/c neophobia in the free exploratory paradigm as an animal model of trait anxiety. Behavioural Pharmacology 1987, 8:541-548.
19. Belzung C., Griebel G. Measuring normal and pathological anxiety-like behaviour in mice: a review. Behavioural Brain Research 2001, 125:141-149.
20. Belzung C. The genetic basis of the pharmacological effects of anxiolytics: a review based on rodent models. Behavioural Pharmacology 2001, 12:451-460.
21. Bergink V., Westenberg H.G. Metabotropic glutamate II receptor agonists in panic disorder: a double blind clinical trial with LY354740. International Clinical Psychopharmacology 2005, 20:291-293.
22. Berman R.M., Cappiello A., Anand A., Oren D.A., Heninger G.R., Charney D.S., Krystal J.H. Antidepressant effects of ketamine in depressed patients. Biological Psychiatry 2000, 47:351-354.
23. Berman R.M., Marcus R.N., Swanink R., McQuade R.D., Carson W.H., Corey-Lisle P.K., Khan A. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. Journal of Clinical Psychiatry 2007, 68:843-853.
24. Berridge K.C., Aldridge J.W., Houchard K.R., Zhuang X. Sequential super-stereotypy of an instinctive fixed action pattern in hyper-dopaminergic mutant mice: a model of obsessive compulsive disorder and Tourette's. BMC Biology 2005, 3:4.
25. Bert B., Fink H., Sohr R., Rex A. Different effects of diazepam in Fischer rats and two stocks of Wistar rats in tests of anxiety. Pharmacology Biochemistry and Behavior 2001, 70:411-420.
26. Bilkei-Gorzó A., Gyertyán I., Lévay G. mCpp-induced anxiety in the light-dark box in rats - a new method for screening anxiolytic activity. Psychopharmacology 1998, 136:291-298.
27. Blaser R.E., Chadwick L., McGinnis G.C. Behavioral measures of anxiety in zebrafish (Danio rerio). Behavioural Brain Research 2010, 208:56-62.
28. Borison R.L., Albrecht J.W., Diamond B.I. Efficacy and safety of a putative anxiolytic agent: ipsapirone. Psychopharmacology Bulletin 1990, 26:207-210.
29. Braida D., Donzelli A., Martucci R., Capurro V., Busnelli M., Chini B., Sala M. Neurohypophyseal hormones manipulation modulate social and anxiety-related behavior in zebrafish. Psychopharmacology 2012, 220:319-330.
30. Brandao M.L., Coimbra N.C., Osaki M.Y. Changes in the auditory-evoked potentials induced by fear-evoking stimulations. Physiology and Behavior 2001, 72:365-372.
31. Bremner J.D. Fluoxetine in depressed patients: a comparison with imipramine. Journal of Clinical Psychiatry 1984, 45:414-419.
32. Briley M., Prost J.F., Moret C. Preclinical pharmacology of milnacipran. International Clinical Psychopharmacology 1996, 11(Suppl. 4):9-14.
33. Broadhurst P.L. The Maudsley reactive and nonreactive strains of rats. A survey. Behavior Genetics 1975, 5:299-319.
34. Brown J.S., Kalish H.I., Farber I.E. Conditioned fear as revealed by magnitude of startle response to an auditory stimulus. Journal of Experimental Psychology 1951, 41:317-328.
35. Brush F.R. The Syracuse strains, selectively bred for differences in active avoidance learning, may be models of genetic differences in trait and state anxiety. Stress 2003, 6:77-85.
36. Cachat J., Stewart A., Grossman L., Gaikwad S., Kadri F., Chung K.M., Wu N., Wong K., Roy S., Suciu C., Goodspeed J., Elegante M., Bartels B., Elkhayat S., Tien D., Tan J., Denmark A., Gilder T., Kyzar E., Dileo J., Frank K., Chang K., Utterback E., Hart P., Kalueff A.V. Measuring behavioral and endocrine responses to novelty stress in adult zebrafish. Nature Protocols 2010, 5:1786-1799.
37. Calabrese J.R., Bowden C.L., Sachs G.S., Ascher J.A., Monaghan E., Rudd G.D. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group. Journal of Clinical Psychiatry 1999, 60:79-88.
38. Campbell K.M., de Lecea L., Severynse D.M., Caron M.G., McGrath M.J., Sparber S.B., Sun L.Y., Burton F.H. OCD-like behaviors caused by a neuropotentiating transgene targeted to cortical and limbic D1+ neurons. Journal of Neuroscience 1999, 19:5044-5053.
39. Carlezon W.A., Mague S.D., Parow A.M., Stoll A.L., Cohen B.M., Renshaw P.F. Antidepressant-like effects of uridine and omega-3 fatty acids are potentiated by combined treatment in rats. Biological Psychiatry 2005, 57:343-350.
40. Champagne D.L., Hoefnagels C.C., de Kloet R.E., Richardson M.K. Translating rodent behavioral repertoire to zebrafish (Danio rerio): relevance for stress research. Behavioural Brain Research 2010, 214:332-342.
41. Chaouloff F., Castanon N., Morméde P. Paradoxical differences in animal models of anxiety among the Roman rat lines. Neuroscience Letters 1994, 182:217-221.
42. Charney D.S., Heninger G.R., Breier A. Noradrenergic function in panic anxiety. Effects of yohimbine in healthy subjects and patients with agoraphobia and panic disorder. Archives of General Psychiatry 1984, 41:751-763.
43. Chaturvedi H.K., Chandra D., Bapna J.S. Interaction between N-methyl-d-aspartate receptor antagonists and imipramine in shock-induced depression. Indian Journal of Experimental Biology 1999, 37:952-958.
44. Chou-Green J.M., Holscher T.D., Dallman M.F., Akana S.F. Compulsive behavior in the 5-HT2C receptor knockout mouse. Physiology and Behavior 2003, 78:641-649.
45. Colombo G., Agabio R., Lobina C., Reali R., Zocchi A., Fadda F., Gessa G.L. Sardinian alcohol-preferring rats: a genetic animal model of anxiety. Physiology and Behavior 1995, 57:1181-1185.
46. Colwill R.M., Creton R. Imaging escape and avoidance behavior in zebrafish larvae. Reviews in the Neurosciences 2011, 22:63-73.
47. Consoni F.T., Vital M.A., Andreatini R. Dual monoamine modulation for the antidepressant-like effect of lamotrigine in the modified forced swimming test. European Neuropsychopharmacology 2006, 16:451-458.
48. Conti L.H., Costello D.G., Martin L.A., White M.F., Abreu M.E. Mouse strain differences in the behavioral effects of corticotropin-releasing factor (CRF) and the CRF antagonist alpha-helical CRF9-41. Pharmacology Biochemistry and Behavior 1994, 48:497-503.
49. Cookson J., Keck P.E., Ketter T.A., Macfadden W. Number needed to treat and time to response/remission for quetiapine monotherapy efficacy in acute bipolar depression: evidence from a large, randomized, placebo-controlled study. International Clinical Psychopharmacology 2007, 22:93-100.
50. Coric V., Feldman H.H., Oren D.A., Shekhar A., Pultz J., Dockens R.C., Wu X., Gentile K.A., Huang S.P., Emison E., Delmonte T., D'Souza B.B., Zimbroff D., Grebb J.A., Goddard A.W., Stock E.G. Multicenter, randomized, double-blind, active comparator and placebo-controlled trial of a corticotropin-releasing factor receptor-1 antagonist in generalized anxiety disorder. Depression and Anxiety 2010, 27:417-425.
51. Costall B., Domeney A.M., Farre A.J., Kelly M.E., Martinez L., Naylor R.J. Profile of action of a novel 5-hydroxytryptamine1A receptor ligand E-4424 to inhibit aversive behavior in the mouse, rat and marmoset. Journal of Pharmacology and Experimental Therapeutics 1992, 262(1):90-98.
52. Craft R.M., Howard J.L., Pollard G.T. Conditioned defensive burying as a model for identifying anxiolytics. Pharmacology Biochemistry and Behavior 1988, 30:775-780.
53. Crawley J., Goodwin F.K. Preliminary report of a simple animal behavior model for the anxiolytic effects of benzodiazepines. Pharmacology Biochemistry and Behavior 1980, 13:167-170.
54. Crespi F. Anxiolytics antagonize yohimbine-induced central noradrenergic activity: a concomitant in vivo voltammetry-electrophysiology model of anxiety. Journal of Neuroscience Methods 2009, 180:97-105.
55. Czéh B., Fuchs E., Simon M. NK1 receptor antagonists under investigation for the treatment of affective disorders. Expert Opinion on Investigation Drugs 2006, 15:479-486.
56. Czyrak A., Rogóz Z., Skuza G., Zajaczkowski W., Maj J. Antidepressant activity of S-adenosyl-l-methionine in mice and rats. Journal of Basic and Clinical Physiology and Pharmacology 1992, 3:1-17.
57. Dahl L.E., Lundin L., le Fèvre Honoré P., Dencker S.J. Antidepressant effect of femoxetine and desipramine and relationship to the concentration of amine metabolites in cerebrospinal fluid. A double-blind evaluation. Acta Psychiatrica Scandinavica 1982, 66:9-17.
58. de Wilde J., Mertens C., Overø K.F., Petersen H.E. Citalopram versus mianserin. A controlled, double-blind trial in depressed patients. Acta Psychiatrica Scandinavica 1985, 72:89-96.
59. Defensor E.B., Pearson B.L., Pobbe R.L., Bolivar V.J., Blanchard D.C., Blanchard R.J. A novel social proximity test suggests patterns of social avoidance and gaze aversion-like behavior in BTBR T+ tf/J mice. Behavioural Brain Research 2011, 217:302-308.
60. DeFries J.C., Hegmann J.P., Halcomb R.A. Response to 20 generations of selection for open-field activity in mice. Behavioral Biology 1974, 11:481-495.
61. Dhara A.K., Suba V., Sen T., Pal S., Nag Chauduri A.K. Preliminary studies on the anti-inflammatory and analgesic activities of the methanolic fraction of the root extract Tragia involucrate. Linn Journal of Ethnopharmacology 2002, 72:265-268.
62. Dierssen M., Gratacos M., Sahun I., Martin M., Gallego X., Amador-Arjona A., Martinez de Lagran M., Murtra P., Marti E., Pujana M.A., Ferrer I., Dalfo E., Martinez-Cue C., Florez J., Torres-Peraza J.F., Alberch J., Maldonado R., Fillat C., Estivill X. Transgenic mice overexpressing the full-length neurotrophin receptor TrkC exhibit increased catecholaminergic neuron density in specific brain areas and increased anxiety-like behavior and panic reaction. Neurobiology of Disease 2006, 24:403-418.
63. Dubé S., Dellva M.A., Jones M., Kielbasa W., Padich R., Saha A., Rao P. A study of the effects of LY2216684, a selective norepinephrine reuptake inhibitor, in the treatment of major depression. Journal of Psychiatric Research 2010, 44:356-363.
64. Ennaceur A., Michalikova S., van Rensburg R., Chazot P.L. Models of anxiety: responses of mice to novelty and open spaces in a 3D maze. Behavioural Brain Research 2006, 174:9-38.
65. Ettenberg A., Geist T.D. Animal model for investigating the anxiogenic effects of self-administered cocaine. Psychopharmacology 1991, 103:455-461.
66. Fabre L.F., McLendon D. The efficacy and safety of nabilone (a synthetic cannabinoid) in the treatment of anxiety. Journal of Clinical Pharmacology 1981, 21(8-9 Suppl.):377S-382S.
67. Fell M.J., Witkin J.M., Falcone J.F., Katner J.S., Perry K.W., Hart J., Rorick-Kehn L., Overshiner C.D., Rasmussen K., Chaney S.F., Benvenga M.J., Li X., Marlow D.L., Thompson L.K., Luecke S.K., Wafford K.A., Seidel W.F., Edgar D.M., Quets A.T., Felder C.C., Wang X., Heinz B.A., Nikolayev A., Kuo M.S., Mayhugh D., Khilevich A., Zhang D., Ebert P.J., Eckstein J.A., Ackermann B.L., Swanson S.P., Catlow J.T., Dean R.A., Jackson K., Tauscher-Wisniewski S., Marek G.J., Schkeryantz J.M., Svensson K.A. N-(4-((2-(trifluoromethyl)-3-hydroxy-4-(isobutyryl)phenoxy)methyl)benzyl)-1-methyl-1H-imidazole-4-carboxamide (THIIC), a novel metabotropic glutamate 2 potentiator with potential anxiolytic/antidepressant properties: in vivo profiling suggests a link between behavioral and central nervous system neurochemical changes. Journal of Pharmacology and Experimental Therapeutics 2011, 336:165-177.
68. Field M.J., Oles R.J., Singh L. Pregabalin may represent a novel class of anxiolytic agents with a broad spectrum of activity. British Journal of Pharmacology 2001, 132:1-4.
69. File S.E., Hyde J.R. Can social interaction be used to measure anxiety?. British Journal of Pharmacology 1978, 62:19-24.
70. File S.E., Zangrossi H., Viana M., Graeff F.G. Trial 2 in the elevated plus-maze: a different form of fear?. Psychopharmacology 1993, 111:491-494.
71. File S.E. Anxiolytic action of a neurokinin1 receptor antagonist in the social interaction test. Pharmacology Biochemistry and Behavior 1997, 58:747-752.
72. Finn D.A., Rutledge-Gorman M.T., Crabbe J.C. Genetic animal models of anxiety. Neurogenetics 2003, 4:109-135.
73. Fontana D.J., Commissaris R.L. Effects of acute and chronic imipramine administration on conflict behavior in the rat: a potential animal model for the study of panic disorder?. Psychopharmacology 1988, 95:147-150.
74. Fresquet A., Sust M., Lloret A., Murphy M.F., Carter F.J., Campbell G.M., Marion-Landais G. Efficacy and safety of lesopitron in outpatients with generalized anxiety disorder. Annals of Pharmacotherapy 2000, 34:147-153.
75. Fukushiro D.F., Mári-Kawamoto E., Aramini T.C., Saito L.P., Costa J.M., Josino F.S., Frussa-Filho R. Withdrawal from repeated treatment with amphetamine reduces novelty-seeking behavior and enhances environmental habituation in mice. Pharmacology Biochemistry and Behavior 2011, 100:180-184.
76. Furey M.L., Drevets W.C. Antidepressant efficacy of the antimuscarinic drug scopolamine: a randomized, placebo-controlled clinical trial. Archives of General Psychiatry 2006, 63:1121-1129.
77. Fuchs E., Flugge G. Experimental animal models for the simulation of depression and anxiety. Dialogues in Clinical Neuroscience 2006, 8:323-333.
78. Fuxe K., Agnati L.F., Bolme P., Hökfelt T., Lidbrink P., Ljungdahl A., Pérez de la Mora M., Ogren S. The possible involvement of GABA mechanisms in the action of benzodiazepines on central catecholamine neurons. Advances in Biochemical Psychopharmacology 1975, 14:45-61.
79. Gannon R.L., Lungwitz E., Batista N., Hester I., Huntley C., Peacock A., Delagrange P., Millan M.J. The benzodiazepine diazepam demonstrates the usefulness of Syrian hamsters as a model for anxiety testing: evaluation of other classes of anxiolytics in comparison to diazepam. Behavioural Brain Research 2011, 218:8-14.
80. Gardner C.R., Piper D.C. Effects of agents which enhance GABA-mediated neurotransmission on licking conflict in rats and exploration in mice. European Journal of Pharmacology 1982, 83:25-33.
81. Gardner C.R. Distress vocalization in rat pups. A simple screening method for anxiolytic drugs. Journal of Pharmacological Methods 1985, 14:181-187.
82. Garner J.P., Weisker S.M., Dufour B., Mench J.A. Barbering (fur and whisker trimming) by laboratory mice as a model of human trichotillomania and obsessive-compulsive spectrum disorders. Comparative Medicine 2004, 54:216-224.
83. Garrick T., Morrow N., Shalev A.Y., Eth S. Stress-induced enhancement of auditory startle: an animal model of posttraumatic stress disorder. Psychiatry 2001, 64:346-354.
84. Geller I., Kulak J.T., Seifter J. The effects of chlordiazepoxide and chlorpromazine on a punishment discrimination. Psychopharmacologia 1962, 3:374-385.
85. Gentsch C., Lichtsteiner M., Feer H. Open-field and elevated-plus maze. A behavioural comparison between spontaneously hypertensive (SHR) and Wistar-Kyoto (WKY) rats and the effects of the chlordiazepoxide. Behavioural Brain Research 1987, 25:389-415.
86. Gerlai R., Fernandes Y., Pereira T. Zebrafish (Danio rerio) responds to the animated image of a predator: towards the development of an automated aversive task. Behavioural Brain Research 2009, 201:318-324.
87. Girgenti M.J., Hunsberger J., Duman C.H., Sathyanesan M., Terwilliger R., Newton S.S. Erythropoietin induction by electroconvulsive seizure, gene regulation, and antidepressant-like behavioral effects. Biological Psychiatry 2009, 66:267-274.
88. Goldberg J.F., Burdick K.E., Endick C.J. Preliminary randomized, double-blind, placebo-controlled trial of pramipexole added to mood stabilizers for treatment-resistant bipolar depression. American Journal of Psychiatry 2004, 161:564-566.
89. Goldberg M.E., Salama A.I., Patel J.B., Malick J.B. Novel non-benzodiazepine anxiolytics. Neuropharmacology 1983, 22:1499-1504.
90. Gower A.J., Falter U., Lamberty Y. Anxiolytic effects of the novel anti-epileptic drug levetiracetam in the elevated plus-maze test in the rat. European Journal of Pharmacology 2003, 481:67-74.
91. Graeff F.G., Netto C.F., Zangrossi H. The elevated T-maze as an experimental model of anxiety. Neuroscience and Biobehavioral Reviews 1998, 23:237-246.
92. Green S., Hodges H. Animal models of anxiety. Behavioural Models in Psychopharmacology 1991, CUP, Cambridge. P. Willner (Ed.).
93. Green M.F., Nuechterlein K.H., Gold J.M., Barch D.M., Cohen J., Essock S., Fenton W.S., Frese F., Goldberg T.E., Heaton R.K., Keefe R.S., Kern R.S., Kraemer H., Stover E., Weinberger D.R., Zalcman S., Marder S.R. Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria. Biological Psychiatry 2004, 56:301-307.
94. Grewal S.S., Shepherd J.K., Bill D.J., Fletcher A., Dourish C.T. Behavioural and pharmacological characterisation of the canopy stretched attend posture test as a model of anxiety in mice and rats. Psychopharmacology 1997, 133:29-38.
95. Griebel G., Belzung C., Perrault G., Sanger D.J. Differences in anxiety-related behaviours and in sensitivity to diazepam in inbred and outbred strains of mice. Psychopharmacology 2000, 148:164-170.
96. Griebel G., Blanchard D.C., Blanchard R.J. Predator-elicited flight responses in Swiss-Webster mice: an experimental model of panic attacks. Progress in Neuro-Psychopharmacology and Biological Psychiatry 1996, 20:185-205.
97. Griebel G., Blanchard D.C., Jung A., Blanchard R.J. A model of 'antipredator' defense in Swiss-Webster mice: effects of benzodiazepine receptor ligands with different intrinsic activities. Behavioural Pharmacology 1995, 6:732-745.
98. Griebel G., Simiand J., Serradeil-Le Gal C., Wagnon J., Pascal M., Scatton B., Maffrand J.P., Soubrie P. Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders. Proceedings of the National Academy of Sciences of the United States of America 2002, 99:6370-6375.
99. Guelfi J.D., Ansseau M., Corruble E., Samuelian J.C., Tonelli I., Tournoux A., Plétan Y. A double-blind comparison of the efficacy and safety of milnacipran and fluoxetine in depressed inpatients. International Clinical Psychopharmacology 1998, 13:121-128.
100. Guidotti A., Dong E., Matsumoto K., Pinna G., Rasmusson A.M., Costa E. The socially isolated mouse: a model to study the putative role of allopregnanolone and 5alpha-dihydroprogesterone in psychiatric disorders. Brain Research. Brain Research Reviews 2001, 37(1-3):110-115.
101. Gyertyán I. Analysis of the marble burying response: marbles serve to measure digging rather than evoke burying. Behavioural Pharmacology 1995, 6:24-31.
102. Haddjeri N., Blier P., de Montigny C. Noradrenergic modulation of central serotonergic neurotransmission: acute and long-term actions of mirtazapine. International Clinical Psychopharmacology 1995, 10(Suppl. 4):11-17.
103. Halaris A.E., Stern W.C., Van Wyck Fleet J., Reno R.M. Evaluation of the safety and efficacy of bupropion in depression. Journal of Clinical Psychiatry 1983, 44:101-103.
104. Hall C.S. Emotional behavior in the rat. I: defecation and urination as measures of individual differences in emotionality. Journal of Comparative Psychology 1934, 18:385-403.
105. Haller J., Aliczki M. Current animal models of anxiety, anxiety disorders, and anxiolytic drugs. Current Opinion in Psychiatry 2012, 25:59-64.
106. Haller J., Bakos N. Stress-induced social avoidance: a new model of stress-induced anxiety?. Physiology and Behavior 2002, 77:327-332.
107. Haller J., Baranyi J., Bakos N., Halász J. Social instability in female rats: effects on anxiety and buspirone efficacy. Psychopharmacology 2004, 174:197-202.
108. Hargreaves G.A., McGregor I.S. Topiramate moderately reduces the motivation to consume alcohol and has a marked antidepressant effect in rats. Alcoholism, Clinical and Experimental Research 2007, 31:1900-1907.
109. Hascoët M., Bourin M. A new approach to the light/dark test procedure in mice. Pharmacology Biochemistry and Behavior 1998, 60:645-653.
110. Heal D.J., Smith S.L. The effects of acute and repeated administration of T3 to mice on 5-HT1 and 5-HT2 function in the brain and its influence on the actions of repeated electroconvulsive shock. Neuropharmacology 1988, 27:1239-1248.
111. Hedges D.W., Brown B.L., Shwalb D.A., Godfrey K., Larcher A.M. The efficacy of selective serotonin reuptake inhibitors in adult social anxiety disorder: a meta-analysis of double-blind, placebo-controlled trials. Journal of Psychopharmacology 2007, 21:102-111.
112. Heinrichs S.C., De Souza E.B., Schulteis G., Lapsansky J.L., Grigoriadis D.E. Brain penetrance, receptor occupancy and antistress in vivo efficacy of a small molecule corticotropin releasing factor type I receptor selective antagonist. Neuropsychopharmacology 2002, 27:194-202.
113. Hine B. Differential open-field reactivity in HAS and LAS rats. Physiology and Behavior 1995, 57:301-306.
114. Holtzheimer P.E., Meeks T.W., Kelley M.E., Mufti M., Young R., McWhorter K., Vito N., Chismar R., Quinn S., Dey S., Byrd E.H., McDonald W.M. A double blind, placebo-controlled pilot study of galantamine augmentation of antidepressant treatment in older adults with major depression. International Journal of Geriatric Psychiatry 2008, 23:625-631.
115. Hovatta I., Barlow C. Molecular genetics of anxiety in mice and men. Annals of Medicine 2008, 40:92-109.
116. Hyttel J. Citalopram - pharmacological profile of a specific serotonin uptake inhibitor with antidepressant activity. Progress in Neuro-Psychopharmacology and Biological Psychiatry 1982, 6:277-295.
117. Inagaki H., Kiyokawa Y., Takeuchi Y., Mori Y. The alarm pheromone in male rats as a unique anxiety model: psychopharmacological evidence using anxiolytics. Pharmacology Biochemistry and Behavior 2010, 94:575-579.
118. Jardim M.C., Nogueira R.L., Graeff F.G., Nunes-de-Souza R.L. Evaluation of the elevated T-maze as an animal model of anxiety in the mouse. Brain Research Bulletin 1999, 48:407-411.
119. Joel D., Avisar A. Excessive lever pressing following post-training signal attenuation in rats: a possible animal model of obsessive compulsive disorder?. Behavioural Brain Research 2001, 123:77-87.
120. Jones B.J., Costall B., Domeney A.M., Kelly M.E., Naylor R.J., Oakley N.R., Tyers M.B. The potential anxiolytic activity of GR38032F, a 5-HT (3) receptor antagonist. British Journal of Pharmacology 1988, 93:985-993.
121. Kaltwasser M.T. Acoustic startle induced ultrasonic vocalization in the rat: a novel animal model of anxiety?. Behavioural Brain Research 1991, 43:133-137.
122. Kalueff A.V., Tuohimaa P. The grooming analysis algorithm discriminates between different levels of anxiety in rats: potential utility for neurobehavioural stress research. Journal of Neuroscience Methods 2005, 143:169-177.
123. Kamei J., Miyata S., Sunohara T., Kamei A., Shimada M., Ohsawa M. Potentiation of the antidepressant-like effect of fluoxetine by aripiprazole in the mouse tail suspension test. Journal of Pharmacological Sciences 2008, 108:381-384.
124. Katoh A., Eigyo M., Ishibashi C., Naitoh Y., Takeuchi M., Ibii N., Ikeda M., Matsushita A. Behavioral and electroencephalographic properties of duloxetine (LY248686), a reuptake inhibitor of norepinephrine and serotonin, in mice and rats. Journal of Pharmacology and Experimental Therapeutics 1995, 272:1067-1075.
125. Katz R.J., Hersh S. Amitriptyline and scopolamine in an animal model of depression. Neuroscience and Biobehavioral Reviews 1981, 5:265-271.
126. Keck M.E., Welt T., Wigger A., Renner U., Engelmann M., Holsboer F., Landgraf R. The anxiolytic effect of the CRH(1) receptor antagonist R121919 depends on innate emotionality in rats. European Journal of Neuroscience 2001, 13:373-380.
127. Keck P.E., Versiani M., Potkin S., West S.A., Giller E., Ice K. Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial. American Journal of Psychiatry 2003, 160(4):741-748. Ziprasidone in Mania Study Group.
128. Kehne J.H., Cain C.K. Therapeutic utility of non-peptidic CRF1 receptor antagonists in anxiety, depression, and stress-related disorders: evidence from animal models. Pharmacology and Therapeutics 2010, 128:460-487.
129. Kellams J.J., Klapper M.H., Small J.G. Trazodone, a new antidepressant: efficacy and safety in endogenous depression. Journal of Clinical Psychiatry 1979, 40(9):390-395.
130. Kennedy S.H., Emsley R. Placebo-controlled trial of agomelatine in the treatment of major depressive disorder. European Neuropsychopharmacology 2006, 16(2):93-100.
131. King J.A., Abend S., Edwards E. Genetic predisposition and the development of posttraumatic stress disorder in an animal model. Biological Psychiatry 2001, 50(4):231-237.
132. King S.M. Escape-related behaviours in an unstable elevated and exposed environment. I: a new behavioural model of extreme anxiety. Behavioural Brain Research 1999, 98:113-126.
133. Klein S., Nicolas L.B., Lopez-Lopez C., Jacobson L.H., McArthur S.G., Grundschober C., Prinssen E.P. Examining face and construct validity of a noninvasive model of panic disorder in Lister-hooded rats. Psychopharmacology 2010, 211:197-208.
134. Knapp D.J., Saiers J.A., Pohorecky L.A. Observations of novel behaviors as indices of ethanol withdrawal-induced anxiety. Alcohol and Alcoholism (Oxford, Oxfordshire). Supplement 1993, 2:489-493.
135. Koba T., Kodama Y., Shimizu K., Nomura S., Sugawara M., Kobayashi Y., Ogasawara T. Persistent behavioural changes in rats following inescapable shock stress: a potential model of posttraumatic stress disorder. The World Journal of Biological Psychiatry 2001, 2:34-37.
136. Koe B.K., Weissman A., Welch W.M., Browne R.G. Sertraline, 1S,4S-N-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthylamine, a new uptake inhibitor with selectivity for serotonin. Journal of Pharmacology and Experimental Therapeutics 1983, 226:686-700.
137. Koks S., Männistö P.T., Bourin M., Shlik J., Vasar V., Vasar E. Cholecystokinin-induced anxiety in rats: relevance of pre-experimental stress and seasonal variations. Journal of Psychiatry and Neuroscience 2000, 25:33-42.
138. Koks S., Vasar E. Deramciclane (Egis). Current Opinion in Investigational Drugs 2002, 3:289-294.
139. Korte S.M., De Boer S.F., Bohus B. Fear-potentiation in the elevated plus-maze test depends on stressor controllability and fear conditioning. Stress 1999, 3:27-40.
140. Kramer M.S., Cutler N.R., Ballenger J.C., Patterson W.M., Mendels J., Chenault A., Shrivastava R., Matzura-Wolfe D., Lines C., Reines S. A placebo-controlled trial of L-365,260, a CCKB antagonist, in panic disorder. Biological Psychiatry 1995, 37:462-466.
141. Kroczka B., Zieba A., Dudek D., Pilc A., Nowak G. Zinc exhibits an antidepressant-like effect in the forced swimming test in mice. Polish Journal of Pharmacology 2000, 52:403-406.
142. Kromer S.A., Kessler M.S., Milfay D., Birg I.N., Bunck M., Czibere L., Panhuysen M., Putz B., Deussing J.M., Holsboer F., Landgraf R., Turck C.W. Identification of glyoxalase-I as a protein marker in a mouse model of extremes in trait anxiety. Journal of Neuroscience 2005, 25:4375-4384.
143. Lader M.H. Ondansetron in the treatment of anxiety. Biological Psychiatry 1991, vol. 2:885-887. Elsevier Science, Amsterdam, Netherlands.
144. Landgraf R., Kessler M.S., Bunck M., Murgatroyd C., Spengler D., Zimbelmann M., Nussbaumer M., Czibere L., Turck C.W., Singewald N., Rujescu D., Frank E. Candidate genes of anxiety-related behavior in HAB/LAB rats and mice: focus on vasopressin and glyoxalase-I. Neuroscience and Biobehavioral Reviews 2007, 31:89-102.
145. Lauritsen B.J., Madsen H. A multinational, double-blind trial with a new antidepressant maprotiline (Ludiomil) and amitriptyline. Acta Psychiatrica Scandinavica 1974, 50:192-201.
146. Lavretsky H., Park S., Siddarth P., Kumar A., Reynolds C.F. Methylphenidate-enhanced antidepressant response to citalopram in the elderly: a double-blind, placebo-controlled pilot trial. American Journal of Geriatric Psychiatry 2006, 14:181-185.
147. Leveleki C., Sziray N., Levay G., Barsvári B., Soproni K., Mikics E., Haller J. Pharmacological evaluation of the stress-induced social avoidance model of anxiety. Brain Research Bulletin 2006, 69:153-160.
148. Levin E.D., Bencan Z., Cerutti D.T. Anxiolytic effects of nicotine in zebrafish. Physiology and Behavior 2007, 90:54-58.
149. Levy A., Kadar T., Dachir S. An animal model for studying therapeutic drugs against post-traumatic stress disorder. Military Medicine 2001, 166(12 Suppl.):74-75.
150. Liberzon I., Krstov M., Young E.A. Stress-restress: effects on ACTH and fast feedback. Psychoneuroendocrinology 1997, 26:443-453.
151. Liebsch G., Montkowski A., Holsboer F., Landgraf R. Behavioral profiles of two Wistar rat lines selectively bred for high or low anxiety-related behaviour. Behavioural Brain Research 1998, 94:301-310.
152. Loiseau F., Le Bihan C., Hamon M., Thiébot M.H. Effects of melatonin and agomelatine in anxiety-related procedures in rats: interaction with diazepam. European Neuropsychopharmacology 2006, 16:417-428.
153. López-Patiño M.A., Yu L., Cabral H., Zhdanova I.V. Anxiogenic effects of cocaine withdrawal in zebrafish. Physiology and Behavior 2008, 93:160-171.
154. López Patiño M.A., Yu L., Yamamoto B.K., Zhdanova I.V. Gender differences in zebrafish responses to cocaine withdrawal. Physiology and Behavior 2008, 95:36-47.
155. Luca R.M., Gerlai R. Animated bird silhouette above the tank: acute alcohol diminishes fear responses in zebrafish. Behavioural Brain Research 2012, 229:194-201.
156. Lydiard R.B., Rickels K., Herman B., Feltner D.E. Comparative efficacy of pregabalin and benzodiazepines in treating the psychic and somatic symptoms of generalized anxiety disorder. International Journal of Neuropsychopharmacology 2010, 13:229-241.
157. Maes M., Vandoolaeghe E., Desnyder R. Efficacy of treatment with trazodone in combination with pindolol or fluoxetine in major depression. Journal of Affective Disorders 1996, 41:201-210.
158. Mahmoud R.A., Pandina G.J., Turkoz I., Kosik-Gonzalez C., Canuso C.M., Kujawa M.J., Gharabawi-Garibaldi G.M. Risperidone for treatment-refractory major depressive disorder: a randomized trial. Annals of Internal Medicine 2007, 147:593-602.
159. Maj J., Chojnacka-Wójcik E., Lewandowska A., Tatarczyńska E., Wiczyńska B. The central action of carbamazepine as a potential antidepressant drug. Polish Journal of Pharmacology and Pharmacy 1985, 37:47-56.
160. Maj J., Rogóz Z., Skuza G., Kołodziejczyk K. Antidepressant effects of pramipexole, a novel dopamine receptor agonist. Journal of Neural Transmission 1997, 104:525-533.
161. Mancinelli A., Borsini F., d'Aranno V., Lecci A., Meli A. Cholinergic drug effects on antidepressant-induced behaviour in the forced swimming test. European Journal of Pharmacology 1988, 158:199-205.
162. Mantovani M., Pértile R., Calixto J.B., Santos A.R., Rodrigues A.L. Melatonin exerts an antidepressant-like effect in the tail suspension test in mice: evidence for involvement of N-methyl-d-aspartate receptors and the l-arginine-nitric oxide pathway. Neuroscience Letters 2003, 343:1-4.
163. Marder S.R. The NIMH-MATRICS project for developing cognition-enhancing agents for schizophrenia. Dialogues in Clinical Neuroscience 2006, 8:109-113.
164. Maurice T., Meunier J., Feng B., Ieni J., Monaghan D.T. Interaction with sigma(1) protein, but not N-methyl-d-aspartate receptor, is involved in the pharmacological activity of donepezil. Journal of Pharmacology and Experimental Therapeutics 2006, 317:606-614.
165. McCloskey T.C., Paul B.K., Commissaris R.L. Buspirone effects in an animal conflict procedure: comparison with diazepam and phenobarbital. Pharmacology Biochemistry and Behavior 1987, 27:171-175.
166. McGrath M.J., Campbell K.M., Burton F.H. The role of cognitive and affective processing in a transgenic mouse model of cortical-limbic neuropotentiated compulsive behavior. Behavioral Neuroscience 1999, 113:1249-1256.
167. McMillin W.P. Oxprenolol in anxiety. Lancet 1973, 1:1193.
168. McMillin W.P. Oxprenolol in the treatment of anxiety due to environmental stress. American Journal of Psychiatry 1975, 132:965-966.
169. Michalikova S., van Rensburg R., Chazot P.L., Ennaceur A. Anxiety responses in Balb/c, c57 and CD-1 mice exposed to a novel open space test. Behavioural Brain Research 2010, 207:402-417.
170. Mikics E., Baranyi J., Haller J. Rats exposed to traumatic stress bury unfamiliar objects - a novel measure of hyper-vigilance in PTSD models?. Physiology and Behavior 2008, 94:341-348.
171. Miskowiak K.W., Vinberg M., Harmer C.J., Ehrenreich H., Knudsen G.M., Macoveanu J., Hansen A.R., Paulson O.B., Siebner H.R., Kessing L.V. Effects of erythropoietin on depressive symptoms and neurocognitive deficits in depression and bipolar disorder. Trials 2010, 11:97.
172. Miyata S., Shimoi T., Hirano S., Yamada N., Hata Y., Yoshikawa N., Ohsawa M., Kamei J. Effects of serotonergic anxiolytics on the freezing behavior in the elevated open-platform test in mice. Journal of Pharmacological Sciences 2007, 105:272-278.
173. Mohapel P., McIntyre D.C. Amygdala kindling-resistant (SLOW) or prone (FAST) rat strains show differential fear responses. Behavioral Neuroscience 1998, 112:1402-1413.
174. Molewijk H.E., Vanderpoel A.M., Mos J., Vanderheyden J.A.M., Olivier B. Conditioned ultrasonic distress vocalizations in adult male rats as a behavioural paradigm for screening anti-panic drugs. Psychopharmacology 1995, 117:32-40.
175. Monn J.A., Valli M.J., Massey S.M., Wright R.A., Salhoff C.R., Johnson B.G., Howe T., Alt C.A., Rhodes G.A., Robey R.L., Griffey K.R., Tizzano J.P., Kallman M.J., Helton D.R., Schoepp D.D. Design, synthesis, and pharmacological characterization of (+)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (LY354740): a potent, selective, and orally active group 2 metabotropic glutamate receptor agonist possessing anticonvulsant and anxiolytic properties. Journal of Medicinal Chemistry 1997, 40:528-537.
176. Montgomery S.A., Loft H., Sánchez C., Reines E.H., Papp M. Escitalopram (S-enantiomer of citalopram): clinical efficacy and onset of action predicted from a rat model. Pharmacology and Toxicology 2001, 88:282-286.
177. Montgomery S.A., Reimitz P.E., Zivkov M. Mirtazapine versus amitriptyline in the long-term treatment of depression: a double-blind placebo-controlled study. International Clinical Psychopharmacology 1998, 13:63-73.
178. Mowla A., Kardeh E. Topiramate augmentation in patients with resistant major depressive disorder: a double-blind placebo-controlled clinical trial. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2011, 35:970-973.
179. Myint A.M., Steinbusch H.W., Goeghegan L., Luchtman D., Kim Y.K., Leonard B.E. Effect of the COX-2 inhibitor celecoxib on behavioural and immune changes in an olfactory bulbectomised rat model of depression. Neuroimmunomodulation 2007, 14:65-71.
180. Nadler J.J., Moy S.S., Dold G., Trang D., Simmons N., Perez A., Young N.B., Barbaro R.P., Piven J., Magnuson T.R., Crawley J.N. Automated apparatus for quantitation of social approach behaviors in mice. Genes Brain and Behavior 2004, 3:303-314.
181. Naukkarinen H., Raassina R., Penttinen J., et al. Deramciclane in the treatment of generalized anxiety disorder: a placebo-controlled, double-blind, dose-finding study. European Neuropsychopharmacology 2005, 15:617-623.
182. Nemets B., Stahl Z., Belmaker R.H. Addition of omega-3 fatty acid to maintenance medication treatment for recurrent unipolar depressive disorder. American Journal of Psychiatry 2002, 159:477-479.
183. Nery F.G., Monkul E.S., Hatch J.P., Fonseca M., Zunta-Soares G.B., Frey B.N., Bowden C.L., Soares J.C. Celecoxib as an adjunct in the treatment of depressive or mixed episodes of bipolar disorder: a double-blind, randomized, placebo-controlled study. Human Psychopharmacology 2008, 23:87-94.
184. Nierenberg A.A., Greist J.H., Mallinckrodt C.H., Prakash A., Sambunaris A., Tollefson G.D., Wohlreich M.M. Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study. Current Medical Research and Opinion 2007, 23:401-416.
185. Njung'e K., Handley S.L. Evaluation of marble-burying behavior as a model of anxiety. Pharmacology Biochemistry and Behavior 1991, 38:63-67.
186. Nowakowska E., Chodera A., Kus K., Rybakowski J. Some behavioural effects of risperidone in rats: comparison with haloperidol. European Neuropsychopharmacology 1999, 9:421-426.
187. Okpanyi S.N., Weischer M.L. Animal experiments on the psychotropic action of a Hypericum extract. Arzneimittel-Forschung 1987, 37:10-13.
188. Onaivi E.S., Green M.R., Martin B.R. Pharmacological characterization of cannabinoids in the elevated plus maze. Journal of Pharmacology and Experimental Therapeutics 1990, 253:1002-1009.
189. Orsetti M., Canonico P.L., Dellarole A., Colella L., Di Brisco F., Ghi P. Quetiapine prevents anhedonia induced by acute or chronic stress. Neuropsychopharmacology 2007, 32:1783-1790.
190. Ottenweller J.E., Natelson B.H., Pitman D.L., Drastal S.D. Adrenocortical and behavioral responses to repeated stressors: toward an animal model of chronic stress and stress-related mental illness. Biological Psychiatry 1989, 26:829-841.
191. Palit G., Kumar R., Chowdhury S.R., Gupta M.B., Saxena R.C., Srimal R.C., Dhawan B.N. A primate model of anxiety. European Neuropsychopharmacology 1998, 8:195-201.
192. Pande A.C., Pollack M.H., Crockatt J., Greiner M., Chouinard G., Lydiard R.B., Taylor C.B., Dager S.R., Shiovitz T. Placebo-controlled study of gabapentin treatment of panic disorder. Journal of Clinical Psychopharmacology 2000, 20:467-471.
193. Papp M., Gruca P., Boyer P.A., Mocaër E. Effect of agomelatine in the chronic mild stress model of depression in the rat. Neuropsychopharmacology 2003, 28:694-703.
194. Papp M., Litwa E., Gruca P., Mocaër E. Anxiolytic-like activity of agomelatine and melatonin in three animal models of anxiety. Behavioural Pharmacology 2006, 17:9-18.
195. Parale M.P., Kulkarni S.K. Clonidine-induced behavioural despair in mice: reversal by antidepressants. Psychopharmacology 1986, 89:171-174.
196. Paré W.P., Tejani-Butt S., Kluczynski J. The emergence test: effects of psychotropic drugs on neophobic disposition in Wistar Kyoto (WKY) and Sprague Dawley rats. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2001, 25:1615-1628.
197. Parra K.V., Adrian J.C., Gerlai R. The synthetic substance hypoxanthine 3-N-oxide elicits alarm reactions in zebrafish (Danio rerio). Behavioural Brain Research 2009, 205:336-341.
198. Pecknold J.C., McClure D.J., Appeltauer L., Wrzesinski L., Allan T. Treatment of anxiety using fenobam (a nonbenzodiazepine) in a double-blind standard (diazepam) placebo-controlled study. Journal of Clinical Psychopharmacology 1982, 2:129-133.
199. Peitsaro N., Kaslin J., Anichtchik O.V., Panula P. Modulation of the histaminergic system and behaviour by alpha-fluoromethylhistidine in zebrafish. Journal of Neurochemistry 2003, 86:432-441.
200. Pellow S., Chopin P., File S.E., Briley M. Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. Journal of Neuroscience Methods 1985, 14:149-167.
201. Piato Â.L., Capiotti K.M., Tamborski A.R., Oses J.P., Barcellos L.J., Bogo M.R., Lara D.R., Vianna M.R., Bonan C.D. Unpredictable chronic stress model in zebrafish (Danio rerio): behavioral and physiological responses. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2011, 35:561-567.
202. Pibiri F., Nelson M., Guidotti A., Costa E., Pinna G. Decreased corticolimbic allopregnanolone expression during social isolation enhances contextual fear: a model relevant for posttraumatic stress disorder. Proceedings of the National Academy of Sciences of the United States of America 2008, 105:5567-5572.
203. Pollack M.H., Worthington J.J., Manfro G.G., Otto M.W., Zucker B.G. Abecarnil for the treatment of generalized anxiety disorder: a placebo-controlled comparison of two dosage ranges of abecarnil and buspirone. Journal of Clinical Psychiatry 1997, 58(Suppl. 11):19-23.
204. Post R.M., Uhde T.W., Roy-Byrne P.P., Joffe R.T. Antidepressant effects of carbamazepine. American Journal of Psychiatry 1986, 143:29-34.
205. Posternak M., Novak S., Stern R., Hennessey J., Joffe R., Prange A., Zimmerman M. A pilot effectiveness study: placebo-controlled trial of adjunctive l-triiodothyronine (T3) used to accelerate and potentiate the antidepressant response. International Journal of Neuropsychopharmacology 2008, 11:15-25.
206. Price K.P. Predictable and unpredictable shock: their pathological effects on restrained and unrestrained rats. Psychological Reports 1972, 30:419-426.
207. Prigol M., Luchese C., Pinton S., Ferreira M., Santos J.P., Karkow A.K., Mortari A.C., Nogueira C.W. Diphenyl diselenide induces anxiolytic-like and sedative effects on the chick social separation-stress behavior. Neuroscience Letters 2011, 495:140-143.
208. Pulliam J.V., Dawaghreh A.M., Alema-Mensah E., Plotsky P.M. Social defeat stress produces prolonged alterations in acoustic startle and body weight gain in male Long Evans rats. Journal of Psychiatric Research 2010, 44:106-111.
209. Pynoos R.S., Ritzmann R.F., Steinberg A.M., Goenjian A., Prisecaru I. A behavioral animal model of posttraumatic stress disorder featuring repeated exposure to situational reminders. Biological Psychiatry 1996, 39:129-134.
210. Quermonne M.A., Nammathao B., Louchahi-Raoul J., Marcy R. Skin conductance reaction (SCR)-habituation test, an elementary model of anxiety as a tool to assess anxiogenic activities of some drugs. Progress in Neuro-Psychopharmacology and Biological Psychiatry 1993, 17:311-318.
211. Rajkumar R., Pandey D.K., Mahesh R., Radha R. 1-(m-Chlorophenyl)piperazine induces depressogenic-like behaviour in rodents by stimulating the neuronal 5-HT(2A) receptors: proposal of a modified rodent antidepressant assay. European Journal of Pharmacology 2009, 608:32-41.
212. Ramboz S., Oosting R., Ait-Amara D., Kung H.F., Blier P., Mendelson M., Mann J.J., Brunner D., Hen R. Serotonin receptor 1A knockout. An animal model of anxiety-related disorder. Proceedings of the National Academy of Sciences of the United States of America 1998, 95:14476-14481.
213. Ramos A., Kangerski A.L., Basso P.F., Da Silva Santos J.E., Assreuy J., Vendruscolo L.F., Takahashi R.N. Evaluation of Lewis and SHR rat strain as a genetic model for the study of anxiety and pain. Behavioural Brain Research 2002, 129:113-123.
214. Rapoport J.L., Ryland D.H., Kriete M. Drug treatment of canine acral lick. An animal model of obsessive-compulsive disorder. Archives of General Psychiatry 1992, 49(7):517-521.
215. Rataud J., Darche F., Piot O., Stutzmann J.M., Böhme G.A., Blanchard J.C. 'Anxiolytic' effect of CCK-antagonists on plus-maze behavior in mice. Brain Research 1991, 548(1-2):315-317.
216. Rau V., DeCola J.P., Fanselow M.S. Stress-induced enhancement of fear learning: an animal model of posttraumatic stress disorder. Neuroscience and Biobehavioral Reviews 2005, 29(8):1207-1223.
217. Redrobe J.P., MacSweeney C.P., Bourin M. The role of 5-HT1A and 5-HT1B receptors in antidepressant drug actions in the mouse forced swimming test. European Journal of Pharmacology 1996, 318(2-3):213-220.
218. Reimherr F.W., Chouinard G., Cohn C.K., Cole J.O., Itil T.M., LaPierre Y.D., Masco H.L., Mendels J. Antidepressant efficacy of sertraline: a double-blind, placebo- and amitriptyline-controlled, multicenter comparison study in outpatients with major depression. Journal of Clinical Psychiatry 1990, 51(Suppl. B):18-27.
219. Rex A., Voigt J.P., Fink H. Behavioral and neurochemical differences between Fischer 344 and Harlan-Wistar rats raised identically. Behavior Genetics 1999, 29:187-192.
220. Reynolds C.F., Butters M.A., Lopez O., Pollock B.G., Dew M.A., Mulsant B.H., Lenze E.J., Holm M., Rogers J.C., Mazumdar S., Houck P.R., Begley A., Anderson S., Karp J.F., Miller M.D., Whyte E.M., Stack J., Gildengers A., Szanto K., Bensasi S., Kaufer D.I., Kamboh M.I., DeKosky S.T. Maintenance treatment of depression in old age: a randomized, double-blind, placebo-controlled evaluation of the efficacy and safety of donepezil combined with antidepressant pharmacotherapy. Archives of General Psychiatry 2011, 68(1):51-60.
221. Richter-Levin G. Acute and long-term behavioral correlates of underwater trauma - potential relevance to stress and post-stress syndromes. Psychiatry Research 1998, 79(1):73-83.
222. Rickels K., Mathew S., Banov M.D., Zimbroff D.L., Oshana S., Parsons E.C., Donahue S.R., Kauffman M., Iyer G.R., Reinhard J.F. Effects of PRX-00023, a novel, selective serotonin 1A receptor agonist on measures of anxiety and depression in generalized anxiety disorder: results of a double-blind, placebo-controlled trial. Journal of Clinical Psychopharmacology 2008, 28(2):235-239.
223. Rickels K., Weisman K., Norstad N., Singer M., Stoltz D., Brown A., Danton J. Buspirone and diazepam in anxiety: a controlled study. Journal of Clinical Psychiatry 1982, 43(12 Pt 2):81-86.
224. Rodgers R.J., Cole J.C., Cobain M.R., Daly P., Doran P.J., Ellis J.R., Wallis P. Anxiogenic-like effects of fluprazine and eltoprazine in the mouse elevated plus-maze: profile comparisons with 8-OH-DPAT, CGS12066B, TFMPP and mCPP. Behavioural Pharmacology 1992, 3:621-634.
225. Rodgers R.J., Shepherd J.K. Influence of prior maze experience on behaviour and response to diazepam in the elevated plus-maze and light/dark tests of anxiety in mice. Psychopharmacology 1993, 113:237-242.
226. Rodgers R.J. Animal models of 'anxiety': where next?. Behavioural Pharmacology 1997, 8(6-7):477-496.
227. Romach M.K., Kaplan H.L., Busto U.E., Somer G., Sellers E.M. A controlled trial of ondansetron, a 5-HT3 antagonist, in benzodiazepine discontinuation. Journal of Clinical Psychopharmacology 1998, 18:121-131.
228. Rosen J.B., Pagani J.H., Rolla K.L., Davis C. Analysis of behavioral constraints and the neuroanatomy of fear to the predator odor trimethylthiazoline: a model for animal phobias. Neuroscience and Biobehavioral Reviews 2008, 32:1267-1276.
229. Roy V., Chapillon P., Jeljeli M., Caston J., Belzung C. Free versus forced exposure to an elevated plus-maze: evidence for new behavioral interpretations during test and retest. Psychopharmacology 2009, 203:131-141.
230. Russell K.H., Hagenmeyer-Houser S.H., Sanberg P.R. Haloperidol-induced emotional defecation: a possible model for neuroleptic anxiety syndrome. Psychopharmacology 1987, 91:45-49.
231. Salak-Johnson J.L., Anderson D.L., McGlone J.J. Differential dose effects of central CRF and effects of CRF astressin on pig behavior. Physiology and Behavior 2004, 83:143-150.
232. Salkind M.R., Hanks G.W., Silverstone J.T. Evaluation of the effects of clobazam, A 1,5 benzodiazepine, on mood and psychomotor performance in clinically anxious patients in general practice. British Journal of Clinical Pharmacology 1979, 7:113S-118S.
233. Salmaggi P., Bressa G.M., Nicchia G., Coniglio M., La Greca P., Le Grazie C. Double-blind, placebo-controlled study of S-adenosyl-l-methionine in depressed postmenopausal women. Psychotherapy and Psychosomatics 1993, 59:34-40.
234. Salomé N., Stemmelin J., Cohen C., Griebel G. Selective blockade of NK2 or NK3 receptors produces anxiolytic- and antidepressant-like effects in gerbils. Pharmacology Biochemistry and Behavior 2006, 83:533-539.
235. Sapronov N.S., Fedotova IuO., Losev N.A. Optimizing effect of the combined administration of 8-OH-DPAT and galantamine on depression-anxiety behavior in old rats with dementia of Alzheimer's type. Eksperimentalnaia i Klinicheskaia Farmakologiia 2006, 69:10-13.
236. Sartori S.B., Hauschild M., Bunck M., Gaburro S., Landgraf R., Singewald N. Enhanced fear expression in a psychopathological mouse model of trait anxiety: pharmacological interventions. PLoS ONE 2011, 6:e16849.
237. Schmidt M.J., Fuller R.W., Wong D.T. Fluoxetine, a highly selective serotonin reuptake inhibitor: a review of preclinical studies. British Journal of Psychiatry 1988, Suppl.(3):40-46.
238. Schmidt U., Sommer H. St. John's wort extract in the ambulatory therapy of depression. Attention and reaction ability are preserved. Fortschritte der Medizin 1993, 111:339-342.
239. Schnörr S.J., Steenbergen P.J., Richardson M.K., Champagne D.L. Measuring thigmotaxis in larval zebrafish. Behavioural Brain Research 2012, 228:367-374.
240. Schoepp D.D., Wright R.A., Levine L.R., Gaydos B., Potter W.Z. LY354740, an mGlu2/3 receptor agonist as a novel approach to treat anxiety/stress. Stress 2003, 6:189-197.
241. Schweizer E., Weise C., Clary C., Fox I., Rickels K. Placebo-controlled trial of venlafaxine for the treatment of major depression. Journal of Clinical Psychopharmacology 1991, 11:233-236.
242. Serfaty M.A., Osborne D., Buszewicz M.J., Blizard R., Raven P.W. A randomized double-blind placebo-controlled trial of treatment as usual plus exogenous slow-release melatonin (6mg) or placebo for sleep disturbance and depressed mood. International Clinical Psychopharmacology 2010, 25:132-142.
243. Sharma A.N., Elased K.M., Garrett T.L., Lucot J.B. Neurobehavioral deficits in db/db diabetic mice. Physiology and Behavior 2010, 101:381-388.
244. Shephard R.A., Broadhurst P.L. Hyponeophagia and arousal in rats: effects of diazepam, 5-methoxy-N,N-dimethyltryptamine, d-amphetamine and food deprivation. Psychopharmacology 1982, 78:368-372.
245. Shepherd J.K., Grewal S.S., Fletcher A., Bill D.J., Dourish C.T. Behavioural and pharmacological characterisation of the elevated zero-maze as an animal model of anxiety. Psychopharmacology 1994, 116:56-64.
246. Shmelkov S.V., Hormigo A., Jing D., Proenca C.C., Bath K.G., Milde T., Shmelkov E., Kushner J.S., Baljevic M., Dincheva I., Murphy A.J., Valenzuela D.M., Gale N.W., Yancopoulos G.D., Ninan I., Lee F.S., Rafii S. Slitrk5 deficiency impairs corticostriatal circuitry and leads to obsessive-compulsive-like behaviors in mice. Nature Medicine 2010, 16:598-602.
247. Singh L., Field M.J., Ferris P., Hunter J.C., Oles R.J., Williams R.G., Woodruff G.N. The antiepileptic agent gabapentin (Neurontin) possesses anxiolytic-like and antinociceptive actions that are reversed by d-serine. Psychopharmacology 1996, 127:1-9.
248. Singh L., Field M.J., Hughes J., Menzies R., Oles R.J., Vass C.A., Woodruff G.N. The behavioural properties of CI-988, a selective cholecystokininB receptor antagonist. British Journal of Pharmacology 1991, 104:239-245.
249. Siwek M., Dudek D., Paul I.A., Sowa-Kućma M., Zieba A., Popik P., Pilc A., Nowak G. Zinc supplementation augments efficacy of imipramine in treatment resistant patients: a double blind, placebo-controlled study. Journal of Affective Disorders 2009, 118:187-195.
250. Skolnick P., Ninan P., Insel T., Crawley J., Paul S. A novel chemically induced animal model of human anxiety. Psychopathology 1984, 17:25-36.
251. Slater E. Genetical factors in neurosis. British Journal of Psychology 1964, 55:265-269.
252. Soroko F.E., Mehta N.B., Maxwell R.A., Ferris R.M., Schroeder D.H. Bupropion hydrochloride ((+/-) alpha-t-butylamino-3-chloropropiophenone HCl): a novel antidepressant agent. Journal of Pharmacy and Pharmacology 1977, 29:767-770.
253. Speedie N., Gerlai R. Alarm substance induced behavioral responses in zebrafish (Danio rerio). Behavioural Brain Research 2008, 188:168-177.
254. Steimer T. Animal models of anxiety disorders in rats and mice: some conceptual issues. Dialogues in Clinical Neuroscience 2011, 13:495-506.
255. Steckler T. Developing small molecule nonpeptidergic drugs for the treatment of anxiety disorders: is the challenge still ahead?. Current Topics in Behavioral Neuroscience 2010, 2:415-428.
256. Stefanini E., Fadda F., Medda L., Gessa G.L. Selective inhibition of serotonin uptake by trazodone, a new antidepressant agent. Life Sciences 1976, 18:1459-1465.
257. Stein D.J., Ahokas A.A., de Bodinat C. Efficacy of agomelatine in generalized anxiety disorder: a randomized, double-blind, placebo-controlled study. Journal of Clinical Psychopharmacology 2008, 28:561-566.
258. Stein M.B., Ravindran L.N., Simon N.M., Liebowitz M.R., Khan A., Brawman-Mintzer O., Lydiard R.B., Pollack M.H. Levetiracetam in generalized social anxiety disorder: a double-blind, randomized controlled trial. Journal of Clinical Psychiatry 2010, 71:627-631.
259. Steiner M.A., Lecourt H., Rakotoariniaina A., Jenck F. Favoured genetic background for testing anxiolytics in the fear-potentiated and light-enhanced startle paradigms in the rat. Behavioural Brain Research 2011, 221:34-42.
260. Stenzel-Poore M.P., Heinrichs S.C., Rivest S., Koob G.F., Vale W.W. Overproduction of corticotropin-releasing factor in transgenic mice: a genetic model of anxiogenic behavior. Journal of Neuroscience 1994, 14:2579-2584.
261. Stephens D.N., Schneider H.H., Kehr W., Andrews J.S., Rettig K.J., Turski L., Schmiechen R., Turner J.D., Jensen L.H., Petersen E.N., Honore T., Bondo Hansen J. Abecarnil, a metabolically stable, anxioselective beta-carboline acting at benzodiazepine receptors. Journal of Pharmacology and Experimental Therapeutics 1990, 253:334-343.
262. Stout J.C., Weiss J.M. An animal model for measuring behavioral responses to anxiogenic and anxiolytic manipulations. Pharmacology Biochemistry and Behavior 1994, 47:459-465.
263. Stratton S.C., Beresford I.J., Harvey F.J., Turpin M.P., Hagan R.M., Tyers M.B. Anxiolytic activity of the tachykinin NK2 receptor antagonists in the mouse light-dark box. European Journal of Pharmacology 1993, 250:R11-R12.
264. Sudak H.S., Maas J.W. Behavioral-neurochemical correlation in reactive and nonreactive strains of rats. Science 1964, 146:418-420.
265. Sun T., He W., Hu G., Li M. Anxiolytic-like property of risperidone and olanzapine as examined in multiple measures of fear in rats. Pharmacology Biochemistry and Behavior 2010, 95:298-307.
266. Szechtman H., Sulis W., Eilam D. Quinpirole induces compulsive checking behavior in rats: a potential animal model of obsessive-compulsive disorder (OCD). Behavioral Neuroscience 1998, 112:1475-1485.
267. Thorsell A., Michalkiewicz M., Dumont Y., Quirion R., Caberlotto L., Rimondini R., Mathé A.A., Heilig M. Behavioral insensitivity to restraint stress, absent fear suppression of behavior and impaired spatial learning in transgenic rats with hippocampal neuropeptide Y overexpression. Proceedings of the National Academy of Sciences of the United States of America 2000, 97:12852-12857.
268. Toubas P.L., Abla K.A., Cao W., Logan L.G., Seale T.S. Latency to enter a mirrored chamber: a novel behavioral assay for anxiolytic agents. Pharmacology Biochemistry and Behavior 1990, 35:121-126.
269. Treit D., Pinel J.P., Fibiger H.C. Conditioned defensive burying: a new paradigm for the study of anxiolytic agents. Pharmacology Biochemistry and Behavior 1981, 15:619-626.
270. Uribe-Marino A., Francisco A., Castiblanco-Urbina M.A., Twardowschy A., Salgado-Rohner C.J., Crippa J.A., Hallak J.E., Zuardi A.W., Coimbra N.C. Anti-aversive effects of cannabidiol on innate fear-induced behaviors evoked by an ethological model of panic attacks based on a prey vs the wild snake Epicrates cenchria crassus confrontation paradigm. Neuropsychopharmacology 2012, 37:412-421.
271. Vogel J.R., Beer B., Clody D.E. A simple and reliable conflict procedure for testing antianxiety agents. Psychopharmacologia 1971, 21:1-7.
272. Wade A., Lemming O.M., Bang Hedegaard K. Escitalopram 10mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care. International Clinical Psychopharmacology 2002, 17:95-102.
273. Wang H., Spiess J., Wong P.T., Zhu Y.Z. Blockade of CRF1 and CCK2 receptors attenuated the elevated anxiety-like behavior induced by immobilization stress. Pharmacology Biochemistry and Behavior 2011, 98:362-368.
274. Wang W., Liu Y., Zheng H., Wang H.N., Jin X., Chen Y.C., Zheng L.N., Luo X.X., Tan Q.R. A modified single-prolonged stress model for post-traumatic stress disorder. Neuroscience Letters 2008, 441:237-241.
275. Watson J.B., Rayner R. Conditioned emotional reactions. Journal of Experimental Psychology 1920, 3:1-14.
276. Woods A., Smith C., Szewczak M., Dunn R.W., Cornfeldt M., Corbett R. Selective serotonin re-uptake inhibitors decrease schedule-induced polydipsia in rats: a potential model for obsessive compulsive disorder. Psychopharmacology 1993, 112:195-198.
277. Yadin E., Friedman E., Bridger W.H. Spontaneous alternation behavior: an animal model for obsessive-compulsive disorder?. Pharmacology Biochemistry and Behavior 1991, 40:311-315.
278. Yardley J.P., Husbands G.E., Stack G., Butch J., Bicksler J., Moyer J.A., Muth E.A., Andree T., Fletcher H., James M.N., et al. 2-Phenyl-2-(1-hydroxycycloalkyl)ethylamine derivatives: synthesis and antidepressant activity. Journal of Medicinal Chemistry 1990, 33:2899-2905.
279. Yeghiayan S.K., Kelley A.E. Serotonergic stimulation of the ventrolateral striatum induces orofacial stereotypy. Pharmacology Biochemistry and Behavior 1995, 52:493-501.
280. Young J.W., Powell S.B., Risbrough V., Marston H.M., Geyer M.A. Using the MATRICS to guide development of a preclinical cognitive test battery for research in schizophrenia. Pharmacology and Therapeutics 2009, 122:150-202.
281. Zethof T.J., Van der Heyden J.A., Tolboom J.T., Olivier B. Stress-induced hyperthermia as a putative anxiety model. European Journal of Pharmacology 1995, 294:125-135.
282. Zivkovic B., Morel E., Joly D., Perrault G., Sanger D.J., Lloyd K.G. Pharmacological and behavioral profile of alpidem as an anxiolytic. Pharmacopsychiatry 1990, 23:108-113.
283. Zoladz P.R., Conrad C.D., Fleshner M., Diamond D.M. Acute episodes of predator exposure in conjunction with chronic social instability as an animal model of post-traumatic stress disorder. Stress 2008, 11:259-281.